GBI Research

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.

Sort by


Global Cardiovascular Disease Drugs Market to 2023 - Expiries, Acquisitions and New Products for Deep Vein Thrombosis, Pulmonary Arterial Hypertension and Dyslipidemia to Shake-Up the Competitive Landscape

01 Dec 2017  |  Published by:  GBI Research
SummaryThe cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within ...
$ 4,995.00 Read More

Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

01 Dec 2017  |  Published by:  GBI Research
SummaryIn 2015 a total of 127,000 transplantations were performed worldwide, an increase of 5.8% from 2014, with 33,000 of these occurring in the EU and 32,000 in the US. Approximately 60% of these were kidney transplants, with liver, heart, lung, pancreas and small bowel transplantations accounting...
$ 6,995.00 Read More

Nutraceuticals: New Applications for Probiotics, Genetic Modification and Diet as Products Make Gains in Rx Territory

01 Dec 2017  |  Published by:  GBI Research
SummaryThe nutraceuticals market is growing and diversifying rapidly. These products are linked by the fact that they are dietary products that have some degree of either purported or clinically evidenced medical benefit. However, the market lacks a clear definition of what constitutes a nutraceutic...
$ 2,995.00 Read More

COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

01 Dec 2017  |  Published by:  GBI Research
SummaryChronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of air flow that interferes with normal breathing. It occurs most often in older people, but can also affect the middle aged population. COPD is a major cause of c...
$ 4,995.00 Read More

Swine and Avian Influenza Drug Development Pipeline Review, 2017

20 Nov 2017  |  Published by:  GBI Research
SummaryThis report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and...
$ 3,995.00 Read More

Sickle Cell Disease Drug Development Pipeline Review, 2017

17 Nov 2017  |  Published by:  GBI Research
SummaryThis report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell ...
$ 3,995.00 Read More

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

16 Nov 2017  |  Published by:  GBI Research
SummaryThis report provides an overview of the Gastric and Esophageal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for each of these cancer types, and features dormant and discontinu...
$ 3,995.00 Read More

Cancer Supportive Care Drug Development Pipeline Review, 2017

14 Nov 2017  |  Published by:  GBI Research
SummaryThis report provides an overview of the Cancer Supportive Care pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cancer anorexia-cachexia syndrome, bone metastasis and cancer pain, an...
$ 3,995.00 Read More

Frontier Pharma: Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD

01 Nov 2017  |  Published by:  GBI Research
SummaryNeurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), lea...
$ 6,995.00 Read More

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

01 Nov 2017  |  Published by:  GBI Research
SummaryHemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four to six times as common as hemophilia B, and more than half of hemophilia A patients have a severe form of hemophilia. The mainstay of treatment for hemophilia is to replace the missing factor VIII ...
$ 4,995.00 Read More

Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders

05 Oct 2017  |  Published by:  GBI Research
SummaryRx-to-OTC switching is the process in which a drug which has formerly been marketed as a prescription-only Rx drug is authorized for sale to the general public, without the need for a prescription. For patients and healthcare providers, OTC products can reduce the cost of medical treatment an...
$ 2,995.00 Read More

Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease

03 Oct 2017  |  Published by:  GBI Research
SummaryThe renal diseases therapy area encompasses a range of diseases of the kidney, such as chronic kidney disease (CKD), acute kidney injury, diabetic nephropathy and focal segmental glomerulosclerosis. Renal diseases are becoming increasingly common due to the increased prevalence of hypertensio...
$ 6,995.00 Read More

Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs

01 Oct 2017  |  Published by:  GBI Research
SummaryThe ophthalmologic therapy area encompasses a wide range of disorders affecting the eye and its supporting structures. These include glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and dry eye syndrome (DES). The therapy area is charac...
$ 6,995.00 Read More

Monoclonal Antibodies - Global Trends in the Competitive, Technological and R&D Landscape

01 Oct 2017  |  Published by:  GBI Research
Summary"Monoclonal Antibodies - Global Trends in the Competitive, Technological and R&D Landscape" discusses both the pipeline and market shares of monoclonal antibodies (mAbs) across a number of therapy areas. mAbs are defined as a collection of antibodies produced from a single B-cell clone. T...
$ 2,995.00 Read More

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

01 Oct 2017  |  Published by:  GBI Research
SummaryDiabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. Chronic hyperglycemia is associated with the long-term damage, dysfunction and fai...
$ 4,995.00 Read More
Total 165 records.